Assenagon Asset Management
NKTR icon

Assenagon Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Assenagon Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-112,487
Closed -$1.58M – 1468
2024
Q1 		$1.58M Sell
112,487
-51,931
-32% -$544K ﹤0.01% 955
2023
Q4 		$1.39M Sell
164,418
-24,613
-13% -$186K ﹤0.01% 1022
2023
Q3 		$1.69M Buy
189,031
+50,330
+36% +$484K 0.01% 915
2023
Q2 		$1.2M Buy
138,701
+94,468
+214% +$1.01M ﹤0.01% 924
2023
Q1 		$466K Buy
44,233
+24,282
+122% +$735K ﹤0.01% 1230
2022
Q4 		$676K Hold
19,951
– – ﹤0.01% 1126
2022
Q3 		$958K Hold
19,951
– – ﹤0.01% 942
2022
Q2 		$1.14M Buy
19,951
+19,026
+2,057% +$1.2M ﹤0.01% 1037
2022
Q1 		$75K Hold
925
– – ﹤0.01% 1386
2021
Q4 		$187K Buy
+925
New +$201K ﹤0.01% 1379
2020
Q4 		– Sell
-13,097
Closed -$3.26M – 1181
2020
Q3 		$3.26M Buy
+13,097
New +$4.12M 0.02% 470
2019
Q2 		– Sell
-5,834
Closed -$2.94M – 1104
2019
Q1 		$2.94M Sell
5,834
-1,308
-18% -$775K 0.03% 417
2018
Q4 		$3.52M Buy
+7,142
New +$4.31M 0.04% 311

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management's NKTR Position: Q2 2024 in Review

Assenagon Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2024, closing a stake of 112,487 shares — an estimated $1.58M sold.

Assenagon Asset Management first reported a position in NKTR in Q4 2018 and held it in 13 quarters. The position peaked at $3.52M in Q4 2018. 133 funds tracked by Wall St. Rank hold NKTR as of Q2 2024.

  • Assenagon Asset Management reported no remaining Nektar Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Assenagon Asset Management sold 112,487 Nektar Therapeutics shares in Q2 2024, an estimated $1.58M.
  • Assenagon Asset Management first reported a position in Nektar Therapeutics in Q4 2018 and held it in 13 quarters.
  • Assenagon Asset Management's Nektar Therapeutics position peaked at $3.52M in Q4 2018.
  • 133 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2024.

Based on Assenagon Asset Management's 13F filing for Q2 2024, filed 18 Jul 2024.